Table 2

Patients characteristics for exploratory, identification and validation studies

Exploratory study	PDAC	CP	LC	BD
n
Total	34	43	20	104
Male	15	36	15	49
Female	19	7	5	55
Age, years
Median	64	50	56	53
IQR	59–71	44–57	46–62	26–59
Stage
0	0
IA	0
IB	1
IIA	4
IIB	8
III	11
IV	10
Histology/cytology
Ductal adenocarcinoma	34
Identification study	PDAC	CP	LC	BD
n
Total	158	159	80	77
Male	102	136	60	51
Female	56	23	20	26
Age, year
Median	70	50	61	55
IQR	62–74	45–55	49–69	52–58
Stage
IA	2
IB	3
IIA	18
IIB	59
III	22
IV	54
Histology/cytology
Ductal adenocarcinoma	158
Validation study	PDAC	CP	Controls
Group
n
Total	79	80	80
Male	37	62	42
Female	42	18	38
Age, years
Median	69	51	68
IQR	61–74	46–57	55–74
Stage
IA	1
IB	0
IIA	11
IIB	28
III	26
IV	13
Histology/cytology
Ductal adenocarcinoma	79

BD, blood donor; control, non-pancreatic disease; CP, chronic pancreatitis; LC, liver cirrhosis; PDAC, pancreatic ductal adenocarcinoma.